A PEER-REVIEWED SUPPLEMENT TO

THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Canadian Guidelines for the Development of Antidementia Therapies (The Background Papers)

2nd Canadian Conference on Antidementia Drug Guidelines

Supplement Editor: Howard H. Feldman
1 Introduction
Howard H. Feldman

3 Canadian Drug Regulatory Framework
L. Kelly, M. Lazzaro, C. Petersen

11 Diagnostic Criteria of Dementia
Rémi W. Bouchard

19 Study Design in Dementia Drug Trials
Chris MacKnight

23 Outcomes for Assessment of Symptomatic and Stabilization/Disease Modifying Drugs
Serge Gauthier

27 Consent in Alzheimer’s Disease Research: Risk/Benefit Factors
B. Lynn Beattie

32 Ethical Considerations for the Conduct of Antidementia Trials in Canada
John D. Fisk

37 Alternatives to Placebo-Controlled Trials
David L. Streiner

42 Target Symptoms and Outcome Measures: Cognition
Andrew Kirk

47 The Role of Functional Assessment as an Outcome Measure in Antidementia Treatment
Fadi Massoud

52 Global Assessment Measures for Assessing Efficacy in Dementia Drug Trials
Kenneth Rockwood

57 Quality of Life in Dementia
Gary Naglie

62 Disease Staging and Milestones
Kiran Rabheru

67 Assessment of Behavioural and Psychological Symptoms Associated with Dementia
David Conn, Lilian Thorpe

72 Biological Markers in Alzheimer’s Disease
Peter Bailey

77 Imaging Biomarkers and their Role in Dementia Clinical Trials
Howard Chertkow, Sandra E. Black

84 Primary Prevention and Delay of Onset of AD/Dementia
Howard H. Feldman, Claudia Jacova

90 Is Mild Cognitive Impairment a Valid Target of Therapy
Kenneth Rockwood, Howard Chertkow, Howard H. Feldman

97 Improving Drug Trials for Mild to Moderate Alzheimer’s Disease
David B. Hogan

103 Treatment of Moderate to Severe Alzheimer’s Disease: Rationale and Trial Design
Nathan Herrmann

109 Clinical Trials in Parkinson’s Disease Dementia and Dementia with Lewy Bodies
Richard Camicioli, Serge Gauthier

118 Frontotemporal Dementia: Recommendations for Therapeutic Studies, Designs, and Approaches
Morris Freedman

125 Therapeutic Issues in Vascular Dementia: Studies, Designs and Approaches
Sandra E. Black
Canadian Guidelines for the Development of Antidementia Therapies

2nd Canadian Conference on Antidementia Drug Guidelines

March 2007

INTRODUCTION

The dementias are recognized to be one of the most important challenges to our aging Canadian society in the 21st century. Scientific progress in understanding of the dementias has been advancing at an unprecedented rate, in turn suggesting that therapies will be developed to prevent, symptomatically treat, and modify their course. This rapid growth of research possibilities brings with it a range of ethical challenges, changing perspectives of risk/benefit and the need for discussion/debate on the best ways to advance the development of antidementia therapies.

Canada is well positioned to address these challenges. There is an integrated network of investigators doing clinical trials within the Consortium of the Canadian Centers for Clinical Cognitive Research (C5R), the Canadian Neurological Society, the Canadian Academy of Geriatric Psychiatry (CAGP) and the Canadian Geriatrics Society (CGS).

In turn, representatives of this network of societies came together for the 2nd Canadian Conference on Antidementia Drug Guidelines in Montreal on October 28-29, 2004 with the goal of developing guidelines to serve as a reference for those involved in developing antidementia therapies.

The overall result of this Conference was published in 2006 as Progress in Clinical Neurosciences: Canadian Guidelines for the Development of Antidementia Therapies: A Conceptual Summary. This supplement now presents the background papers that were developed by participants of the Conference. Each paper was initially presented for discussion and later finalized through peer review to their current state. Many topics reflect the early days of therapeutic development and much more will need to be said about them over time. In turn, it can be anticipated that updating of these Guidelines will be required. These Guidelines are unique. Prior to their peer review they had received active input from representatives of the respective clinical and research groups: the regulatory authorities of the Central Nervous System (CNS) Division of the Therapeutic Products Directorate (TPD of Health Canada), the Alzheimer Society of Canada and the pharmaceutical industry.

On behalf of the contributors I trust that you will find the supplement stimulating and worthy of further discussion and feedback as we face the need to develop treatments for this burgeoning problem of dementia.

Howard H. Feldman
Division of Neurology
University of British Columbia
Vancouver, BC, Canada
ACKNOWLEDGEMENTS


The Conference gratefully acknowledges the role of MedPlan in assisting in the planning, logistics, and organization of this Conference and in assisting in the editing and formatting of this publication.

DISCLOSURE

Within the past 2 years Dr. Feldman has had operating grant funding from the Canadian Institutes of Health Research (CIHR), as well as having served as consultant, received grant funding or participated in CME programs sponsored by Astra Zeneca, Pfizer, Eisai, Novartis, Janssen, Servier, Sanofi Synthelabo, Lilly, GlaxoSmithKline, Myriad, Targacept, Forest, Lundbeck and Axonyx.

REFERENCES